SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
1. SAB Biotherapeutics will present at EASD 2025, focusing on T1D therapies. 2. Four oral presentations showcase SAB-142's unique disease-modifying capabilities. 3. SAB-142 aims to delay and potentially prevent type 1 diabetes progression. 4. EASD is the largest diabetes conference, attracting global professionals. 5. SAB BIO utilizes a unique production method for high-potency immunoglobulins.